Andy Glasebrook

Andy Glasebrook has a diverse and extensive work experience. Andy served as the Vice President of Autoimmune Drug Development at Toralgen starting in July 2020, following an advisory role in the same company. Prior to this, they worked as a Consultant at AGbio Consulting, LLC from January 2020. Their career also includes being a Senior Research Fellow at Eli Lilly and Company for over three decades until their retirement in August 2017. Additionally, Andy has held positions such as President at the Inflammation Research Association, an Assistant Professor in Cancer Biology at The Salk Institute, and a Postdoctoral Fellow at the Swiss Institute for Experimental Cancer Research.

Andy Glasebrook graduated from Carleton College in 1974 with a BA in Biology. Andy then went on to pursue a PhD in Immunology at The University of Chicago Pritzker School of Medicine, graduating in 1980.